2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2755 Tafasitamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma (R/R FL) in the United States real-world setting

Narendranath Epperla, MD, MS, FACP, Sarah Lucht2, Bruce Feinberg, DO3, Julie Wu4, Camryn Craig5, Kim Saverno, PhD, RPh6
1 Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States
2 Cardinal Health, Dublin, Ohio, United States
3 Cardinal Health, Dublin, Ohio, United States
4 Incyte Corporation, Wilmington, Delaware, United States
5 Cardinal Health, Dublin, Ohio, United States
6 Incyte Corporation, Wilmington, Delaware, United States

Introduction: Tafasitamab (tafa), a CD19-targeting monoclonal antibody (mAb), is indicated in combination with lenalidomide and rituximab (R2) for adults with R/R FL. Tafa+R2 received approval in the United States (US) in June 2025 based on results from inMIND, a phase 3, randomized, placebo-controlled trial, which demonstrated statistically significant improvement in progression-free survival for tafa+R2 vs placebo+R2. Approximately 1 year since approval, real-world (RW) evidence for patients with R/R FL receiving tafa+R2 in community settings remains limited. This RW study aimed to describe patient characteristics and treatment patterns among patients with R/R FL treated with tafa+R2 in US community practices.

Methods: This retrospective, multisite, physician-abstracted chart review study included adults who initiated tafa+R2 as second-line (2L) or third-line (3L) treatment for R/R FL in a community setting on or after March 1, 2025. All regimen components had to be initiated ≤28 days of one another, or tafa was added to ongoing R2. Patients had no prior tafa exposure, no evidence of transformed lymphoma, and ≥3 months of follow-up after tafa initiation, unless death occurred earlier. Community physicians from Cardinal Health’s Oncology Provider Extended Network abstracted data from patient medical records into electronic case report forms in chronological order by tafa initiation date (up to 10 patients per physician). Data were summarized descriptively for all patients with grade 1-3A FL.

Results: Participating community physicians (N=32) predominantly practiced in medium or large practices (22 [68.8%]) and estimated treating a median of 10 study-eligible patients (Q1, Q3: 5, 13). Most participating physicians (28 [87.5%]) reported administering bispecific antibodies for lymphoma at their practice, indicating availability of advanced immunotherapy options within participating community settings.

Data were abstracted for 224 patients who received tafa+R2 for R/R FL (median follow-up time: 5.0 months [Q1, Q3: 4.0, 7.1]). Most patients (176 [78.6%]) received tafa+R2 as 2L therapy; the median age at tafa+R2 initiation was 67.3 years (Q1, Q3: 62.1, 73.3). 160 patients (71.4%) were White, 39 (17.4%) were Black, and 186 (83.0%) were of non-Hispanic ethnicity. Most patients had Ann Arbor stage III-IV disease (220 [98.2%]), ECOG performance status of 0-1 (184 [82.1%]), and were classified as high risk (161 [71.9%]) per the FL International Prognostic Index (FLIPI, score 3-5) at tafa+R2 initiation.

The majority of patients (152 [67.9%]) received bendamustine + rituximab as initial systemic treatment for FL, and all patients had received an anti-CD20 mAb prior to tafa+R2. Progression of disease within 24 months of initial FL diagnosis was reported for 45 patients (20.1%). Median treatment-free interval between discontinuation of the prior line of therapy and tafa+R2 initiation was 25.7 months (Q1, Q3: 9.4, 45.8) overall, with 28.2 months (Q1, Q3: 13.5, 50.9) and 10.1 months (Q1, Q3: 2.1, 26.8) observed for 2L and 3L patients, respectively. The median time from initial FL diagnosis to tafa initiation was 4.3 years (Q1, Q3: 2.5, 5.9). Most patients (216 [96.4%]) initiated tafa, lenalidomide, and rituximab together, with 8 patients (3.6%) adding tafa to an ongoing R2 regimen. The majority of patients (155 [69.2%]) initiated lenalidomide as part of tafa+R2 at a 20-mg dose; 36 (16.1%) and 31 (13.8%) patients initiated at 15 mg and 10 mg, respectively. For the 69 patients with lenalidomide dosing <20 mg, renal insufficiency was the most common reason (33 [47.8%]). At last follow-up, 195 patients (87.1%) remained on tafa+R2-based therapy.

Conclusions: This RW study provides the first insights into adoption of tafa+R2 for patients with R/R FL treated in US community practices. Despite the availability of bispecific antibodies, tafa+R2 was utilized across participating practices, supporting its integration into contemporary treatment pathways. Patients receiving tafa+R2 in community settings were broadly similar to those included in the inMIND clinical trial, though a greater proportion of RW patients had high-risk disease per FLIPI score and poorer ECOG performance status. Most patients remained on tafa+R2-based therapy at last follow-up, providing early evidence of treatment persistence in routine community practice. Longer follow-up is needed to evaluate clinical outcomes associated with tafa+R2 for R/R FL in community settings.

Narendranath Epperla, MD, MS, FACP: CRISPR Therapeutics - Research Funding; BeOne - Research Funding; AbbVie - Research Funding; Ipsen - Research Funding; Incyte - Research Funding; ADC Therapeutics - Research Funding; ADC Therapeutics - Research Funding; Eli Lilly - Research Funding; Genetech - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)